Amgen Earns Neutral Rating from Cantor Fitzgerald

Analysts maintain price target of $350 on the biotech stock

Apr. 8, 2026 at 1:29pm

Got story updates? Submit your updates here. ›

Cantor Fitzgerald reiterated a 'neutral' rating and set a $350.00 price target on shares of Amgen, the global biotechnology company, in a research note on Wednesday. The analysts' rating and price objective point to a potential upside of 2.94% from Amgen's current stock price.

Why it matters

Amgen is one of the largest and most influential biotech companies, with a diverse portfolio of biologic medicines used in oncology, nephrology, bone health, and other therapeutic areas. Analysts' ratings and price targets on Amgen stock are closely watched by investors as indicators of the company's performance and future prospects.

The details

In their research note, the Cantor Fitzgerald analysts reaffirmed their 'neutral' rating on Amgen, citing the company's current stock price and future growth potential. The $350 price target represents a modest increase from Amgen's recent trading levels around $340 per share. Other Wall Street firms have also weighed in on Amgen, with some maintaining 'buy' ratings and higher price objectives, while a minority have issued 'sell' recommendations.

  • Cantor Fitzgerald issued the research note on Wednesday, April 8, 2026.

The players

Amgen

A global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. Amgen focuses on discovering, developing, manufacturing, and delivering human therapeutics that address serious illnesses, with an emphasis on biologic medicines derived from cellular and molecular biology.

Cantor Fitzgerald

An investment bank and financial services firm that provides research coverage and ratings on Amgen and other publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will continue to monitor Amgen's stock performance and any further updates or changes to analyst ratings and price targets on the company.

The takeaway

Amgen's neutral rating from Cantor Fitzgerald reflects the mixed views on Wall Street about the company's near-term growth prospects, despite its position as a leading biotech firm. Analysts will likely focus on Amgen's pipeline, regulatory approvals, and financial results as key drivers of the stock price in the coming quarters.